Rapport Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
RAPP$26.07+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $56,805 | $70,169 |
| Short-term investments | 248,475 | 77,309 |
| Restricted cash | 105 | 85 |
| Prepaid expenses and other current assets | 4,417 | 3,309 |
| Total current assets | 309,802 | 150,872 |
| Property and equipment, net | 3,529 | 1,916 |
| Operating lease right of use asset, net | 1,442 | 2,084 |
| Other assets | 160 | 551 |
| Total assets | $314,933 | $155,423 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable (1) | $1,954 | $2,502 |
| Accrued expenses and other current liabilities (1) | 6,076 | 5,631 |
| Operating lease liability | 737 | 670 |
| Total current liabilities | 8,767 | 8,803 |
| Series B preferred stock tranche right liability | — | 4,200 |
| Operating lease liability, net of current portion | 739 | 1,476 |
| Total liabilities | 9,506 | 14,479 |
| Commitments and contingencies (Note 13) | ||
| Series A convertible preferred stock, $0.001 par value; zero and 100,182,354 shares authorized as of December 31, 2024 and 2023, respectively; zero shares and 100,182,354 shares issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of zero and $100,182 as of December 31, 2024 and 2023, respectively | — | 89,487 |
| Series B convertible preferred stock, $0.001 par value; zero and 89,431,030 shares authorized as of December 31, 2024 and 2023, respectively; zero and 51,273,790 shares issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of zero and $86,000 as of December 31, 2024 and 2023, respectively | — | 77,091 |
| Stockholders’ equity (deficit) | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares and zero shares authorized at December 31, 2024 and 2023, respectively; zero shares issued and outstanding at both December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares and 250,000,000 shares authorized at December 31, 2024 and 2023, respectively; 36,580,202 shares and 4,170,817 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 37 | 4 |
| Additional paid-in capital | 429,657 | 19,796 |
| Accumulated other comprehensive income (loss) | (522) | 4 |
| Accumulated deficit | (123,745) | (45,438) |
| Total stockholders’ equity (deficit) | 305,427 | (25,634) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $314,933 | $155,423 |
(1)
Includes related party amounts ofzero and$0.2 million (accounts payable) andzero (accrued expenses) as of both December 31, 2024 and 2023, respectively (see Notes 5 and 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.